I love a good routine. Every morning, I have a cup of tea and a bowl of oatmeal for breakfast, and I’ve been doing that for at least 10 years. It’s super satisfying, and I see no reason to change it. Every night, my husband, John, and I watch “Jeopardy!”…
A wearable sensor that’s designed to monitor and improve swallowing led to increased swallowing frequency for people with Parkinson’s disease in a small clinical study. The scientists believe the sensors are useful for continuous monitoring of swallowing dysfunction, or dysphagia, in Parkinson’s, and may be a way to help…
Tavapadon, an orally available small molecule being developed for Parkinson’s disease, was generally safe and eased motor symptoms within one month of being administered at either a fixed or flexible dose to adults with early-stage disease. It also reduced the risk of common side effects typically associated with similar classes…
A new study in juvenile zebra finches — a songbird species known for singing to attract mates — shows that mastering complex natural behaviors like singing depends on dopamine, a key signaling chemical that is lacking in the brains of people with Parkinson’s disease. The findings of this novel…
Vyalev (foscarbidopa and foslevodopa) demonstrated a favorable long-term safety and tolerability profile, along with sustained motor symptom control, in Parkinson’s disease patients who participated in the extension part of a Phase 3 trial (NCT03781167). Results from nearly two years of the extension study (NCT04379050) showed…
Caregiving for a loved one is one of the most challenging, demanding, and often frustrating jobs that I can think of. My husband, Eric, and I never anticipated that I’d be his caregiver, but Parkinson’s disease changed our reality. I’ve learned that caring for someone is one of the…
U.S. researchers have identified a novel way to block a protein known as DLK, or dual leucine-zipper kinase, that may offer a promising strategy to protect neurons from degeneration — which, the team notes, could pave the way for safer and more precise treatments for neurodegenerative conditions like Parkinson’s…
Arvinas has begun a Phase 1 clinical trial to test its investigational therapy ARV-102 in people with Parkinson’s disease, with Phase 1 data in healthy adults showing it was safe and worked as expected. ARV-102 is being developed for neurodegenerative conditions where the leucine-rich repeat kinase 2, or…
Spinal cord stimulation failed to improve walking ability despite multiple attempts in a small group of people with Parkinson’s disease who experienced freezing of gait — a symptom where the feet suddenly feel stuck and unable to move forward — according to the researchers running the study. The study…
Pretzel Therapeutics has launched a Phase 1 clinical trial to study PX578, a therapy designed to boost the function of mitochondria, the cell’s energy-producing powerhouses, and address conditions caused by faulty energy production. These include rare genetic conditions and neurodegenerative disorders like Parkinson’s and Alzheimer’s. The…
Get regular updates to your inbox.
